Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumor.
Imai H, Kaira K, Hashimoto K, Nitanda H, Taguchi R, Yanagihara A, Umesaki T, Yamaguchi O, Mouri A, Kawasaki T, Yasuda M, Kobayashi K, Sakaguchi H, Kuji I, Kagamu H. Imai H, et al. Among authors: kagamu h. Cancer Med. 2021 Sep;10(18):6317-6326. doi: 10.1002/cam4.4176. Epub 2021 Aug 7. Cancer Med. 2021. PMID: 34363337 Free PMC article.
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K; North East Japan Study Group. Usui K, et al. Among authors: kagamu h. Lung Cancer. 2016 Sep;99:131-6. doi: 10.1016/j.lungcan.2016.07.003. Epub 2016 Jul 5. Lung Cancer. 2016. PMID: 27565928 Clinical Trial.
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O, Kaira K, Mouri A, Shiono A, Hashimoto K, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Yamaguchi O, et al. Among authors: kagamu h. Cancer Chemother Pharmacol. 2019 May;83(5):817-825. doi: 10.1007/s00280-019-03790-w. Epub 2019 Feb 13. Cancer Chemother Pharmacol. 2019. PMID: 30758646
Spontaneous aspiration of a long tree twig as foreign body.
Hashimoto K, Kaira K, Kobayashi K, Murayama Y, Kagamu H. Hashimoto K, et al. Among authors: kagamu h. Respirol Case Rep. 2019 Feb 1;7(3):e00401. doi: 10.1002/rcr2.401. eCollection 2019 Apr. Respirol Case Rep. 2019. PMID: 30766681 Free PMC article.
Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.
Mouri A, Kaira K, Shiono A, Yamaguchi O, Murayama Y, Kobayashi K, Kagamu H. Mouri A, et al. Among authors: kagamu h. Thorac Cancer. 2019 Apr;10(4):1005-1008. doi: 10.1111/1759-7714.13022. Epub 2019 Mar 11. Thorac Cancer. 2019. PMID: 30859745 Free PMC article.
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Hashimoto K, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Uchida T, et al. Among authors: kagamu h. Thorac Cancer. 2019 Apr;10(4):975-979. doi: 10.1111/1759-7714.13039. Epub 2019 Mar 12. Thorac Cancer. 2019. PMID: 30864291 Free PMC article.
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Miura Y, Shiono A, Nishihara F, Murayama Y, Noda SE, Kato S, Kobayashi K, Kagamu H. Yamaguchi O, et al. Among authors: kagamu h. Thorac Cancer. 2019 Apr;10(4):992-1000. doi: 10.1111/1759-7714.13044. Epub 2019 Mar 19. Thorac Cancer. 2019. PMID: 30888716 Free PMC article.
193 results